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ABSTRACT
Bromodeoxyuridine (5-bromo-20-deoxyuridine,
BrdU) is a halogenated nucleotide of low toxicity
commonly used to monitor DNA replication. It is
considered a valuable tool for in vitro and in vivo
studies, including the detection of the small popula-
tion of neural stem cells (NSC) in the mammalian
brain. Here, we show that NSC grown in self-
renewing conditions in vitro, when exposed to
BrdU, lose the expression of stem cell markers like
Nestin, Sox2 and Pax6 and undergo glial differenti-
ation, strongly up-regulating the astrocytic marker
GFAP. The onset of GFAP expression in BrdU
exposed NSC was paralleled by a reduced expres-
sion of key DNA methyltransferases (DNMT) and a
rapid loss of global DNA CpG methylation, as we
determined by our specially developed analytic
assay. Remarkably, a known DNA demethylating
compound, 5-aza-20-deoxycytidine (Decitabine),
had similar effect on demethylation and differenti-
ation of NSC. Since our key findings apply also to
NSC derived from murine forebrain, our observa-
tions strongly suggest more caution in BrdU uses
in stem cells research. We also propose that BrdU
and its related substances may also open new
opportunities for differentiation therapy in oncology.
INTRODUCTION
Ongoing neurogenesis in the mammalian brain is thought
to depend on neural stem cells (NSC), which reside in few
specialized areas of the adult brain, such as the
subventricular and subgranular zones (1). Extensive
in vivo and in vitro studies involving NSC have shown
that these cells are capable of differentiating into all
major brain cell types: neurons and glia, namely astrocytes
and oligodendrocytes (2). The process of differentiation is
associated with the loss of neural stem cell markers, such
as the intermediate ﬁlament Nestin and the transcription
factors Sox2 and Pax6 (2). In this study, we employed
NSC derived from mouse embryonic stem (ES) cells,
which reliably recapitulate the features of brain NSC (2).
These NSC represent a fast growing, self-renewing and
homogenous cell line, not susceptible to spontaneous dif-
ferentiation under normal, fetal calf serum (FCS)-free
culture conditions. Controlled exposure of NSC to the
growth factor-rich FCS results in a rapid induction of
astrocyte-speciﬁc intermediate ﬁlament GFAP and astro-
cytic differentiation (2,3). This model system has therefore
several advantages compared to neurosphere or ex vivo
assays in which self-renewing NSC are continuously
undergoing spontaneous differentiation, thus eventually
becoming a minority of the total cell population.
Neural stem cells (NSC) were discovered as the only
DNA-replicating cells of the mammalian brain, initially
through the incorporation of radioactive
3H isotopes
(4,5). Later on, bromodeoxyuridine (5-bromo-20-
deoxyuridine, BrdU), a halogen-containing thymidine
analogue which can become incorporated into the
replicating DNA and detected by immunochemical
analysis using speciﬁc antibodies (6) has been exploited
to detect DNA-synthesizing and therefore proliferating
cells in the brain (7–9), and has since then become the
reagent of choice for these uses.
Despite the fact that BrdU was used clinically for as-
sessment of glioma proliferation (10), its genotoxic side
effects are also known. Already in the 1960s, BrdU was
recognized to cause chromosomal constrictions (i.e. sites
of very densely packed chromatin, similarly to centromere
regions) in leukocyte cultures (11,12). Currently, BrdU is
also employed as a radio-sensitizing agent in oncology,
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DNA cross-links upon subsequently applied ionizing ra-
diation (13). On its own, BrdU was reported to negatively
affect the growth of cancer cells without affecting their
viability (14,15). The tenets and caveats of BrdU as a
genotoxic agent are known, yet it is still widely used in
the neurobiological research studies due to its apparent
low toxicity (16).
DNA methylation and demethylation is an important
and tightly controlled process in stem cells (17,18).
Changes in methylation status of cytosines in so-called
CpG islands at gene regulatory regions determine the
expression of differentiation-relevant genes (19). DNA
methylation is ensured by DNA methyltransferase
(DNMT) enzymes, which add methyl groups to CpG cyto-
sines, either de novo (DNMT3a and DNMT3b) or in the
newly replicated DNA in order to maintain existing CpG
methylation patterns (DNMT1) (18). DNA demethylation
isachievedeitherbyexchangeofmethylatedcytosinesorby
inhibited DNMT activity upon DNA replication (17) and
can then stimulate the transcriptional activation of affected
genes. Indeed, genome-wide DNA demethylation was
shown to be associated with differentiation of neural stem
and cancer cells (20,21). So far, BrdU’s possible effect on
DNAmethylationwasrarelystudied(22),andincontextof
stem cells, it has not been apparently addressed yet.
MATERIALS AND METHODS
Derivation of murine neural stem cell lines
Cell lines were derived from murine embryonic stem
cells (ESC) based on protocols established by A. Smith’s
laboratory (2,23). Initially, ESC were grown in feeder-free
conditions on high-glucose DMEM, supplemented with
15% fetal calf serum (FCS, PAN Biotech), recombinant
LIF supernatant, 0.1mM b-mercaptoethanol, 2mM
L-glutamine (L-Gln), 100 U/ml penicillin and 100mg/ml
streptomycin (P/S). In the ﬁrst step, ESC were seeded on
gelatinized dishes in N2B27 culture medium (1:1 DMEM/
F12 and Neurobasal medium (Invitrogen), supplemented
with 0.5  N2 supplement (Invitrogen) and 0.5  B27 sup-
plement (Invitrogen), 0.1mM b-mercaptoethanol, L-Gln
and P/S. Medium was changed daily without passaging
for7days.Inthesecondstep,coloniesweregentlydislodged
using Accutase (Sigma Aldrich), washed with PBS, gently
resuspended in NSC culture medium (see below), then
transferred at high density into culture ﬂasks. There, after
2 days of culturing, formation of neurospheres could be
observed. Neurospheres were disrupted by Accutase treat-
ment and gentle pipeting and transferred to cell culture
dishes in NSC culture medium. Adherently outgrowing
NSC were expanded into stable cell lines through several
passages ( 20) before being used for experiments.
Cell culture and treatments
Murine ES-derived NSC and murine forebrain NSC,
kindly provided by Luciano Conti (2) were grown in
Euromed-N cell culture medium (Euroclone), supple-
mented with 2mM L-Gln and P/S, 1  N2 supplement
(Invitrogen), 20ng/ml murine EGF and FGF2 (ProSpec,
Israel) at 5% CO2 and 37 C. In the case of forebrain NSC,
cell culture dishes with coated with 0.2% porcine gelatine
(Sigma Aldrich). BrdU, CldU and IdU (Sigma Aldrich)
100  stock solutions were prepared in H2O at 330mM.
5-Aza-20-deoxycytidine (5-aza, also known as Decitabine,
Tocris Bioscience) was dissolved in water and applied at
0.5mM ﬁnal concentration. Astrocyte differentiation and
culture medium was DMEM/F12 with L-Gln and P/S,
supplemented with 10% FCS.
Gene expression analysis
Total RNA was extracted from live cells with Trizol
reagent (Invitrogen), precipitated with isopropanol and
ethanol and dissolved in DEPC-treated water
(Invitrogen). One micrograms of total RNA [as quantiﬁed
with NanoVue device, General Electric (GE)] was used for
retrotranscription using VILO reverse transcription kit
(Invitrogen) according to manufacturer’s instructions
and without RNAse treatment. RT-minus reactions
(without reverse transcriptase enzyme) were also
prepared. Estimated 20ng of cDNA in 25ml reaction
volume were analyzed in triplicate by quantitative
RT-PCR ampliﬁcation on a Light Cycler 480 system
(Roche) using SYBR Green assay (QuantiFast SYBR
Green PCR Kit, Qiagen) according to manufacturer’s in-
structions and for 40 cycles. CT-values were obtained by
calculation of the second derivative using Light Cycler 480
software (Roche) and normalized among samples against
a housekeeping gene b-2-microglobulin (B2M). RT-minus
preparations proved to be negative. Forward and reverse
primers (FP and RP) were designed with Roche
UniversalProbe Library software against Mus musculus:
B2M: FP: CTGCAGAGTTAAGCATGCCAGTA; RP:
TCACATGTCTCGATCCCAGTAGA
DNMT1: FP: CAGAGACTCCCGAGGACAGA; RP: T
TTACGTGTCGTTTTTCGTCTC
DNMT3A: FP: ACACAGGGCCCGTTACTTCT; RP:
TCACAGTGGATGCCAAAGG
DNMT3B: FP: GAATGCGCTGGGTACAGTG; RP: G
CCACCAGTTTGTCAGCAG
Ki67: FP: GCTGTCCTCAAGACAATCATCA; RP: G
GCGTTATCCCAGGAGACT
Nestin: FP: CTGCAGGCCACTGAAAAGTT; RP: TCT
GACTCTGTAGACCCTGCTTC
Sox2: FP: TGCTGCCTCTTTAAGACTAGGG; RP: TC
GGGCTCCAAACTTCTCT
Pax6: FP: GTTCCCTGTCCTGTGGACTC; RP: ACCG
CCCTTGGTTAAAGTCT
GFAP: FP: TGGAGGAGGAGATCCAGTTC; RP: AG
CTGCTCCCGGAGTTCT
Tuj1: FP: GCGCATCAGCGTATACTACAA; RP: CAT
GGTTCCAGGTTCCAAGT
MBP: FP: GGCACGCTTTCCAAAATCT; RP: CCAT
GGGAGATCCAGAGC
Flow cytometry
Fluorescence-activated cell sorting (FACS) acquisition
and analysis were performed on BD FACScalibur using
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(5me-C) assay, cells were ﬁxed in 75% ethanol (1h,
4 C). CpG epitope was made accessible by heating the
cells in dH2Oa t9 0  C for 50. Cells were then washed
with 1% bovine serum albumin (BSA) in PBS and
stained with either mouse anti-BrdU antibody (preference
for CldU, #347580, BD Biosciences), rat anti-BrdU (pref-
erence for IdU, #ab6326, Abcam) or sheep anti-5me-C
antibody (#GTX21884, Genetex), followed by
ﬂuorophore-labeled secondary antibody (Invitrogen).
For DNA content and apoptotic DNA fragmentation
assay, ethanol-ﬁxed cells were stained with propidium
iodide (Sigma Aldrich), signal was measured on a linear
or logarithmic scale, respectively. Cell cycle phase distri-
bution was calculated using ModFit software.
Immunoblotting
Cells were lysed in NP40 lysis buffer (1% NP40, 50mM
Tris–Cl pH 8, 150mM NaCl, 2mM EDTA, 1mM DTT,
1mM NaF, 100mMN a 2VO4 and protease inhibitor
cocktail (Roche). 40mg of whole cell lysate in La ¨ mmli
loading buffer were resolved by SDS-PAGE, transferred
to nitrocellulose membranes (Protran) using Biorad elec-
trophoresis systems and probed with primary and second-
ary antibodies in 5% bovine serum albumin (BSA) and
skimmed milk, respectively. Primary antibodies used were:
Nestin (#611658, BD Biosciences), GFAP (#Z0334 Dako),
Pax6 (#PRB-278P, Covance), Vinculin (#V4505, Sigma
Aldrich).
Immunoﬂuorescence microscopy
Cells cultured on glass cover slips were ﬁxed in 4% para-
formaldehyde (PFA) in PBS (100 at room temperature),
permeabilized with 0.2% Triton X100, blocked with
0.5% BSA and 0.2% gelatin in PBS, then probed with
appropriate primary antibodies and Alexa-ﬂuor 488- and
647-labeled secondary antibodies (Invitrogen). Primary
antibodies used were: Nestin (#MAB353, Millipore),
GFAP (#Z0334 Dako); Ki67 antibody (Alexa-ﬂuor 488
labelled, #561165, BD Biosciences). For BrdU detection,
incubation with DNAse I (NEB) was performed together
with the primary anti-BrdU antibody (#347580, BD
Biosciences) in order to retrieve the epitope. For
5me-C and BrdU detection, cells were ﬁxed for 50 in
methanol and rehydrated with PBS. Epitopes were
retrieved by 2M HCl treatment for 300 at 37 C.
Residual HCl was inactivated with borax buffer (0.1M
Na2B4O7, pH 8.5), staining was performed as above,
using anti-BrdU antibody and anti-5me-C antibody
described above. DNA was counterstained with DAPI
(Sigma Aldrich). Confocal images were obtained with a
Leica TCS SP2 AOBS confocal laser microscope by se-
quential scanning and processed with Leica LAS AF
Lite software; wide ﬁeld images with an Olympus
AX70 upright microscope and processed with ImageJ
software.
RESULTS
BrdU induces cell cycle arrest in NSC
In our study, we employed embryonic stem cell-derived
NSC (2), which serve as a reliable model for radial
glia stem cells present in the subvetricular zone of the
mammalian brain. These cells are self-renewing and
undifferentiated over numerous passages (24), while
tripotent in their capacity to differentiate in a controlled
manner into glial cells (astrocytes and oligodendrocytes,
Supplementary Figure S1A) and neurons (Supplementary
Figure S1B). In order to address the impact of BrdU
exposure on NSC physiology, we applied this reagent at
a concentration of 3.3mM, as commonly used for DNA
labeling and cell proliferation studies. In all our BrdU
exposure experiments, NSC were continuously cultured
in their growth medium purposefully designed to
maintain their self-renewal capacity (2), and were not in-
tentionally subjected to any known differentiation stimuli.
Immediately after its administration, BrdU became
rapidly incorporated into the DNA of NSC and already
after 8h of exposure, nearly half of the cells became
BrdU-positive, and at 72h, practically, all cells showed a
strong BrdU signal in their nuclei (Figure 1A and B).
Strikingly though, our growth kinetics studies showed
that the proliferation of BrdU-treated cells was
markedly impaired when compared to control NSC
which proliferated exponentially and in fact had to be
passaged twice within the 7 days of the experiment
(Figure 1D). By analyzing their cell cycle distribution,
we observed that BrdU-treated cells progressively
accumulated in 2N state and the percentage of cells in
S-phase decreased already after 24h of BrdU exposure
and even more so at day 3 (Figure 1D and
Supplementary Figure S2A). Correspondingly, at the
same time point, cells ceased to express Ki67, a widely
used proliferation marker, as detected both by reduced
gene expression and at the single cell level
(Supplementary Figure S2B and Figure 1E and F). Both
these sets of data indicate that BrdU-exposed NSC exit
the cell cycle and arrest in the G1/G0 phase.
We have next investigated at which concentrations
BrdU’s cytostatic effect becomes apparent. Strikingly,
within 3 days, as little as 100nM BrdU was enough
to reduce NSC proliferation by more than half,
and 300nM lead to an 8-fold decrease (Figure 1G).
Furthermore, we discovered that also the BrdU-related
halogenated deoxyuridine (Hal-dU) compounds,
5-chloro-20-deoxyuridine (CldU) and 5-iodo-20-
deoxyuridine (IdU) displayed similar cytostatic effects
on NSC (Figure 1H). We exploited this observation and
the possibility to detect these two different Hal-dU by two
speciﬁc antibodies (25), to quantify the DNA synthesis
rates. Proliferating NSC were exposed to either com-
pounds for 48h and then switched to the other one for
the following 24h. Hal-dU incorporation into cells was
detected by either of two BrdU-targeted antibodies from
different species origin, of which one has a much stronger
afﬁnity to CldU over IdU and another has higher prefer-
ence for IdU (25). Flow cytometrical analysis revealed that
while nearly all cells incorporated the ﬁrst compound in
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Figure 1. BrdU is a potent cytostatic agent in NSC, with a rather moderate toxicity. (A) Wide-ﬁeld microscopy analysis of BrdU incorporation
kinetics in NSC. At T0 h, cell culture medium was supplemented with BrdU. Cells were ﬁxed at given time points and analyzed by immunoﬂuor-
escence using a BrdU-speciﬁc antibody. (B) Quantiﬁcation of BrdU incorporation kinetics as representatively shown in (A). Cells displaying a clear
nuclear BrdU signal were counted as positive. (C) Growth curve of NSC, treated with BrdU or H2O (ctrl). About 10
5 cells were seeded for both
treatments in parallel in triplicate. At given time points, cells were detached and total cell number was calculated. Note: ctrl cells were split twice, on
day 2 and 5 due to conﬂuency, while BrdU treated cells never reached conﬂuency. Error bars show SD. (D) Quantiﬁcation of DNA content and
cell cycle phase distribution in ctrl and BrdU-treated cells at different time points as analyzed by linear propidium iodide signal acquisition by ﬂow
cytometry and quantiﬁed using ModFit software. Error bars show SD of a triplicate experiment. (E) Wide-ﬁeld microscopy analysis of immuno-
ﬂuorescence staining of control and BrdU-treated NSC using Alexa-ﬂuor coupled Ki67 antibody. (F) Quantiﬁcation of Ki67 positive cells in the
control and BrdU-treated population as representatively shown in (E). (G) Titration of BrdU effect of cell proliferation. About 10
5 cells were seeded
in medium supplemented with H2O or increasing range of BrdU (0.03–3.3mM). On day 3, total cell number was assessed and the relative cell
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(continued)the initial 48h, only a small percentage of cells took up the
other Hal-dU compound supplied later. The order of
addition of a Hal-dU compound was inconsequential
(Figure 1H). In summary, we were able to detect a signiﬁ-
cant decrease in NSC proliferation already after 48h of
Hal-dU exposure. Also, the toxicity of CldU and IdU as
determined by the analysis of Sub-G1 DNA fragmentation
was low (data not shown), comparable to BrdU, with
which we never detected more than 10% of cells displaying
apoptotic DNA fragmentation (Figure 1I).
BrdU induces astrocytic differentiation in NSC
When we inspected with closer scrutiny the nature of the
BrdU-induced cell cycle arrest, we detected signs consistent
with astrocytic differentiation in these cells. Shortly after
the beginning of BrdU treatment, we could observe charac-
teristic changes in cellular morphology (i.e. increase in cell
size and astrocyte-like stellate cell appearance), loss of
Nestin (a known marker of NSC) and strong up-regulation
of GFAP, a marker typical of astrocytes (Figure 2A).
Hence, we performed a kinetics analysis of Nestin and
GFAP expression by immunoﬂuorescence (IF) and
western blotting. Immunoﬂuorescence quantiﬁcation
revealed that 72h of BrdU exposure are sufﬁcient to
induce loss of Nestin expression in nearly 90% of NSC,
while at the same time point approximately one-third of
NSC has become GFAP positive; these values were
roughly retained in the following 4 days of observation
(Figure 2B). Also by western blotting, we observed an
inverse correlation between the progressive loss of Nestin
(and the NSC-speciﬁc transcriptional factor Pax6) and the
concomitant increase of GFAP protein expression (Figure
2C). In addition, by analyzing by quantitative real time
RT-PCR (qRT-PCR) the expression of the stem cell
markers Nestin, Sox2 and Pax6, and the differentiation
marker GFAP speciﬁc for astrocytes (2) at 72h after
BrdU treatment, we observed a strong reduction of
Nestin, Sox2 and Pax6 gene expression and a 100-fold
up-regulation of the astrocyte marker GFAP (Figure 2D).
Consistent with these observations, the BrdU-related com-
pounds CldU and IdU had a similar effect on the loss of
stem cell markers and the induction of astrocytic differen-
tiation (Figure 2D).
Hal-dUs are modiﬁed nucleotides, which become
incorporated into DNA during replication. Unexpectedly,
however, the uridine residue of BrdU was reported not
only to compete with thymidine during DNA replication
but also with cytidine (26), thus becoming incorporated
against guanine as well as adenine residues of the DNA
(27,28). We have tested whether a moderate excess of thy-
midine or cytidine (10mM, a triple concentration of that of
BrdU) would impact on stem cell physiology. While BrdU
lead to a strong drop or decrease in numbers of Nestin or
GFAP positive cells, respectively, no such effect was
observed with thymidine or cytidine (Supplementary
Figure S3). However, modiﬁed cytidine analogues, such
as cytosine arabinoside (Ara-C) and
5-aza-20-deoxycytidine (5-aza, also known as Decitabine),
were shown to induce differentiation in cancer cells (29)
and embryonic stem cells (30,31) or stem cells from the
umbilical cord (32), respectively. Ara-C proved highly
toxic for NSC (data not shown), also 5-aza had a rather
high toxicity in NSC, when compared to BrdU
(Supplementary Figure S4A). However, we observed
that NSC which survived 5-aza treatment arrested their
cell cycle (Supplementary Figure S4B) and underwent
glial differentiation. In agreement with this, 5-aza-treated
cells showed a clear reduction in Nestin, Sox2 and Pax6
stem cell gene expression as detected by qRT-PCR and a
signiﬁcant up-regulation of GFAP, all to a level similar to
BrdU-treated cells (Figure 2E). Furthermore, we detected
some ectopic expression of the oligodendrocyte gene
MBP, which is commonly absent in NSC, while
neuronal marker Tuj1 was not up-regulated in these con-
ditions (Figure 2E).
BrdU induces DNA demethylation
5-aza is primarily used in the cancer therapy for its ability
to arrest tumour growth by inducing DNA demethylation
(33); indeed, it was conﬁrmed as an efﬁcient DNA
demethylating agent in neurosphere assays (21). Following
these observations, we analyzed BrdU-exposed NSC for
their global DNA methylation status. Strikingly, we
detected a strong decrease of the signal generated by a
speciﬁc antibody against 5-methyl-20-deoxycytidine
(5me-C) in BrdU-treated NSC as compared to control
cells, indicating a comparatively reduced CpG methyla-
tion status (Figure 3A). In order to further address this
effect more quantitatively, we set on to develop a new
method for studying relative changes of global CpG
DNA methylation, based on speciﬁc antibody against
5-methyl-20-deoxycytidine (5me-C) and FACS. Here,
5me-C epitope is unmasked by hypotonic thermal de-
naturation of nuclear DNA, at temperatures exceeding
the melting threshold of BrdU-substituted DNA (34).
Also here we addressed the changes in global DNA methy-
lation relatively to its status in untreated proliferating
NSC. We hence arbitrarily set the gates for ‘medium’
DNA methylation so as to include most control untreated
NSC, while cell nuclei outside this gate were considered as
hypo- or hyper-methylated (Figure 3C). Remarkably,
already 24h after exposure to BrdU, more than half of
Figure 1. Continued
number increase versus cells seeded was calculated. Error bars show SD of a triplicate experiment. (H) Flow cytometrical analysis for BrdU-related
compounds CldU and IdU which also induce cell cycle arrest in NSC. Cell were treated ﬁrst with one of the substances for 48h, then with the other
for 24h, ﬁxed and stained with a mouse-anti-BrdU antibody [preference for CldU (25)] or rat-anti-BrdU antibody [preference for IdU (25)]. Note the
strongly reduced degree of incorporation of either compound when added last. Error bars show SD of a triplicate experiment. (I) Flow cytometrical
analysis of NSC for apoptosis-associated DNA fragmentation (Sub-G1). Time course study in triplicate of BrdU-treated NSC. Cells were scored for
DNA content of less than 2N, as detected with propidium iodide, measured on log10 scale. Error bars show SD. Note the rather low percentage of
apoptotic cells at all time points.
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below the medium gate, indicating a loss of global CpG
methylation. This loss of DNA methylation persisted also
at day 3 and even on the day 7 of BrdU treatment (Figure
3C and D). Remarkably, also 5-aza prompted a clear
increase in the hypomethylated population of cells, thus
conﬁrming both its role as DNA demethylating agent also
in a culture of homogenous self-renewing NSC and the
reliability of the DNA methylation analytic assay we
have developed (Figure 3D). Furthermore, also the other
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Figure 2. NSC treated with BrdU rapidly lose the expression of stem cell markers and differentiate into astrocytes. (A) Confocal microscopy analysis
of immunoﬂuorescence staining of control and BrdU-treated NSC. GFAP-speciﬁc antibody (red) was used to visualize astrocytic differentiation.
Note that while ctrl NSC are Nestin positive (green), the antibody against Nestin shows no signal in BrdU treated cells. Bar: 15mm.
(B) Immunoﬂuorescence-based kinetics of Nestin and GFAP expression in BrdU-treated NSC. Cells were stained with speciﬁc antibodies and
scored for the Nestin or GFAP signal positivity in triplicate for each time point. Blue line, Nestin positive cells; red line, GFAP positive cells.
Error bars show SD of a triplicate experiment. (C) Western blot analysis of NSC for the kinetics of stem cell (Nestin, Pax6) and astrocyte (GFAP)
relevant protein expression upon BrdU treatment. Membranes were normalized for vinculin. (D) Quantitative RT-PCR analysis of NSC treated with
with BrdU and BrdU-related reagents CldU and IdU. Gene expression of stem cell markers (Nestin, Sox2, Pax6) and astrocyte differentiation marker
(GFAP) was normalized against untreated NSC. b2-microglobulin (b2M) was used as housekeeping gene, error bars show SD. (E) Quantitative
RT-PCR analysis of NSC treated with BrdU or 5-aza-20-deoxycytidine (5-aza). Gene expression of stem cell markers (Nestin, Sox2 and Pax6) and
differentiation markers (GFAP for astrocytes, Tuj1 for neurons and MBP for oligodendrocytes) was normalized against untreated NSC. b2M was
used as housekeeping gene, error bars show SD.
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Figure 3. BrdU treatment leads to a loss of global CpG methylation in NSC. (A) Wide-ﬁeld microscopy analysis of immunoﬂuorescence staining of
control and BrdU-treated NSC. BrdU was detected with a speciﬁc antibody (green, note the absence of nuclear signal in ctrl cells). Speciﬁc antibody
for 5-methyl-20-deoxycytidin (5me-C) was used to detect global DNA methylation at CpG sites (red). Representative images are shown.
(B) Representative ﬂow cytometrical analyses of NSC for the relative changes in global DNA methylation upon exposure to BrdU at 24h and
72h. Global DNA methylation at CpG islands was detected with same antibody as in (A). Cy5-coupled secondary antibody signal was measured on
log10 scale. Gates were set to discriminate ‘medium’ methylated cells, while the population migrations out of this gate were classiﬁed as ‘hypo-’ or
‘hyper-methylated’. (C) Statistical quantiﬁcation of the ﬂow cytometrical data representatively shown in (B). The kinetics of BrdU treated NSC and
NSC treated with 5-aza for 7 days are shown. Gates were set as described above; same gate set was used for all measurements of each experiment
done in triplicate. Error bars show SD. (D) Expression kinetics of the main DNA methyltransferases (DNMT) and differentiation marker GFAP in
BrdU treated NSC, as measured by qRT-PCR analysis and normalized against untreated NSC. b2M was used as housekeeping gene, error bars show
SD. (E) Flow cytometrical analysis of NSC for the relative changes in global DNA methylation. Shown is the kinetics of serum (FCS) treated NSC
in order to induce astrocytic differentiation. Acquisition and gating were set as in (D). (F) Quantitative RT-PCR analysis of expression of the 2
cell-cycle independent DNA methyltransferases (DNMT) in FCS-treated NSC, normalized against untreated NSC. b2M was used as housekeeping
gene, error bars show SD.
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DNA demethylation of NSC (Supplementary Figure
S5A). Noteworthy, in all cases the hypomethylation gate
corresponded to the negative control of cells stained with
the secondary antibody alone (Supplementary Figure
S5A), indicating that the loss of global DNA methylation
may be nearly total for the cells in this gate.
Interestingly, in our FACS assay, the quantity of
hypomethylated cells observed upon BrdU treatment
was as high as in 5-aza-treated cells, used as positive
control: this indicates the efﬁcacy of BrdU as a
DNA-demethylating agent. At the same time, BrdU
proved signiﬁcantly less toxic than 5-aza (Supplementary
Figure S4A). We next aimed to determine whether the
DNA methylation machinery is affected in BrdU-treated
NSC, and we therefore examined the expression of the
main DNA methyltrasferases (DNMTs): DNMT1 and
the related enzymes DNMT3a and DNMT3b. Our
qRT-PCR analyses revealed that all these three enzymes
were unchanged after 8h of BrdU exposure, but became
progressively down-regulated at later time points
(Figure 3E and Supplementary Figure S5B). This is
insofar remarkable since only DNMT1 is known to be
down-regulated in non-proliferating cells, while
DNMT3a/3b expression is reportedly cell-cycle independ-
ent (18). Moreover, the observed DNMT down-regulation
coincided in its rate and temporal progression with the
increased expression of the differentiation marker GFAP
(Figure 3E). Our data hence correlate the loss of global
CpG methylation, the down-regulation of all three key
DNMTs and the astrocytic differentiation in BrdU-
treated NSC.
Both 5-aza (35) and BrdU (14) were reported to induce
DNA damage and activate the DNA damage response
[DDR, (36)] signaling in cancer cells. We have recently
shown that NSC are fully DDR proﬁcient in response to
DNA double strand breaks (3). However, when we tested
DDR activation in BrdU-exposed NSC, we could not
detect any foci formation of 53BP1, gH2AX or any focal
kinase activity of Ataxia telangiectasia mutated (ATM)
neither after 24h nor 3 days (Supplementary Figure S6A
and S6B). In fact, ATM was found to be down-regulated
at the transcriptional level (Supplementary Figure S6C),
in agreement with our recent report on suppressed ATM
expression and DDR activity in astrocytes (3). The lack
of DDR activity in BrdU-exposed NSC can hence be inter-
preted as further supporting evidence of their differenti-
ation into astrocytes.
It may be argued that the loss of global DNA methyla-
tion is a general feature associated with astrocytic differ-
entiation or exit from cell cycle. If that is the case,
demethylation induced by BrdU might be the indirect
outcome of arrested cell cycle and/or differentiation.
However, when we analyzed the levels of global DNA
methylation of NSC exposed to FCS, a treatment
known to lead to their rapid cell-cycle exit and terminal
differentiation into astrocytes (2,3), we did not detect any
enrichment for cells with hypomethylated DNA
(Figure 3F). Of course, growth factor-stimulated astro-
cytic differentiation of NSC is still likely to be associated
with promoter-speciﬁc DNA methylation changes (37),
but our data indicate that this is distinct from the global
DNA demethylation observed following BrdU. Moreover,
astrocytes, unlike BrdU-exposed NSC, retain stable
mRNA levels of the two cell cycle independent DNMT
enzymes, DNMT3a and DNMT3b, when compared with
proliferating NSC (Figure 3G). Therefore, we conclude
that astrocytic differentiation or cell cycle exit per se
does not require and is not intrinsically associated with
decreased global methylation in NSC.
BrdU impact on forebrain NSC
Finally, we were able to recapitulate our key observations
in an ex vivo NSC model system. Here, we employed
adherently growing murine NSC derived from the mouse
forebrain, which in their characteristics and culture con-
ditions widely resemble ES-derived NSC (2). Also these
cells readily incorporated BrdU (Figure 4A) and at day
3 showed signs of cell cycle arrest, as determined by a
decrease of the percentage of cells in S-phase and the
Ki67 gene expression (Figure 4B and C). Remarkably,
also in these forebrain NSC, the expression of DNMT1,
3a and 3b was down-regulated upon BrdU exposure, simi-
larly to ES-derived NSC (Figure 4C). Consistent with the
results described above, in BrdU-treated forebrain NSC,
we detected reduced expression of stem cell markers
Nestin, Sox2 and Pax6, while neuronal marker Tuj1 was
not induced and, moreover, the glial genes GFAP and
MBP were found up-regulated when compared to
control forebrain NSC (Figure 4D). We were also able
to detect some GFAP up-regulation on protein level
(Supplementary Figure S7A) despite the fact that unlike
ES-derived and fetal NSC, these forebrain NSC express
detectable endogenous levels of GFAP (Supplementary
Figure S7B) due to their particular origin from adult
brain (1). In summary, also NSC derived from a mouse
brain arrest proliferation, lose the expression of DNMTs
and stem cell genes and show signs of glial gene induction
when exposed to BrdU.
DISCUSSION
In this study, we show that BrdU is readily incorporated
into proliferating NSC, without activating canonical
DNA-damage response signaling or provoking signiﬁcant
toxicity. However, already after 24h of exposure of NSC
to moderate levels of BrdU, NSC proliferative capacity
diminishes and this is paralleled by widespread loss of
global DNA CpG methylation. Ultimately, BrdU causes
the loss of stem cell characteristics and the profound in-
duction of glial, mainly astrocytic, differentiation. Here,
the tendency to undergo glial, and not neural differenti-
ation in the absence of appropriate cues may be explained
by the so-called ‘glial identity of the neural stem cells’ (1),
thus making an astrocytic differentiation the default
choice for these cells. Furthermore, we show that this
outcome is stable over time and that both commonly
used BrdU-related halogenated deoxyuridines CldU and
IdU had comparable effects on DNA methylation and
astrocytic differentiation. Finally, we show that BrdU
affects forebrain NSC in a very similar manner.
Nucleic Acids Research, 2012,Vol.40, No. 12 5339At this stage, it is unclear whether BrdU has a direct or
an indirect cytostatic effect on NSC. The former may be
brought about by inhibition of DNA polymerase activity
and hence DNA replication by this thymidine analogue,
while the latter may be caused by DNA demethylation. Of
course, both direct and indirect effects may co-operate in
arresting cell proliferation. Cytostatic effects of BrdU
onto cell lines have been reported before (38). Several
studies have demonstrated BrdU’s impact on proliferation
rate and cellular senescence in cancer cells (14,15,39). Two
recent studies on NSC have shown that also BrdU treat-
ment of neurosphere cultures resulted in their cell cycle
arrest, reduction of neurosphere size and cellular senes-
cence (40,41). The latter study also demonstrated that
BrdU-exposed neurospheres did not undergo neuronal
or oligodendrocytical differentiation when stimulated to
do so, while their capacity to undergo growth
factor-stimulated astrocytic differentiation was even
slightly increased (40). However, our study had the
unique important distinguishing feature of employing a
homogenous adherent population of tri-potent,
self-renewing NSC (2), and, hence, is unaffected by the
potentially confounding effects of differentiating cells
commonly present in neurospheres. Due to this key ad-
vantage, we were able to detect two main changes trig-
gered by BrdU in NSC: loss of global methylation and
astrocytic differentiation.
Importantly, this astrocytic differentiation was achieved
in an unmodiﬁed NSC culture medium (aside from
BrdU addition), which stimulates proliferation and
self-renewal and inhibits differentiation of NSC, without
any additional exposure to any known differentiation-
inducing growth factors or stimuli. Indeed, the certain
delayed toxicity of BrdU did coincide with the onset of
ectopic differentiation, which in turn may have affected
the viability of the cells in their pro-proliferative and
differentiation-suppressing culture medium. This culture
medium conﬂict may explain why many of BrdU
exposed cells remain in a kind of transition state, where
their minimal cytoplasmic Nestin levels are not detectable
anymore while their differentiation has not proceeded
as far as to identify them as GFAP positive. Hence,
C
D
A
0.01
0.1
1
10
l
o
g
 
c
h
a
n
g
e
v
s
 
c
t
r
l
f
o
r
e
b
r
a
i
n
N
S
C
Forebrain NSC BrdU d3
Nestin    Sox2     Pax6     GFAP     Tuj1       MBP    
BrdU
BrdU
DNA
DNA
forebrain NSC ctrl
forebrain NSC BrdU d3
0.1
1
l
o
g
 
c
h
a
n
g
e
v
s
 
c
t
r
l
a
d
u
l
t
N
S
C
Forebrain NSC BrdU d3
Ki67    1      3a     3b 
DNMT ctrl BrdU d3
0
20
40
60
80
100
%
 
o
f
c
e
l
l
s
B Cell cycle distribution
Figure 4. Forebrain-derived NSC also undergo cell cycle arrest upon BrdU exposure and lose the expression of stem cell and DNMT genes.
(A) Confocal microscopy analysis of BrdU incorporation in cultured forebrain NSC, immunoﬂuorescence performed using a BrdU-speciﬁc
antibody. Bar: 20mm. (B) Quantiﬁcation of DNA content and cell cycle phase distribution in ctrl and BrdU-treated forebrain NSC at day 3 as
analyzed by linear propidium iodide signal acquisition by ﬂow cytometry and quantiﬁed using ModFit software. Error bars show SD of a triplicate
experiment. (C) Quantitative RT-PCR gene expression analysis of the proliferation marker Ki67 and the three DNMTs in BrdU exposed forebrain
NSC, normalized against untreated forebrain NSC. b2M was used as housekeeping gene, error bars show SD. (D) Quantitative RT-PCR analysis of
BrdU-treated forebrain NSC. Gene expression of stem cell markers (Nestin, Sox2 and Pax6) and differentiation markers (GFAP for astrocytes, Tuj1
for neurons and MBP for oligodendrocytes) was normalized against untreated forebrain NSC. b2M was used as housekeeping gene, error bars show
SD.
5340 Nucleic Acids Research, 2012,Vol.40, No. 12a number of cells in our immunoﬂuorescence assay were
determined as Nestin negative but not GFAP positive.
The same may apply to DNA methylation, since also
our methylation detection assay may have its limits of
sensitivity.
The mechanism by which BrdU affects DNA CpG
methylation in a manner similar to 5-aza is presently
unclear. Indeed, 5-aza is a modiﬁed cytosine, hence
being chemically able to interfere in the CpG-methylation
pathway (42), while BrdU is generally considered as a thy-
midine analogue. Interestingly, however, research per-
formed in the 1980s has shown that BrdU competes with
cytidine during DNA replication (26), and can be
incorporated to a high extent against guanine residues,
resulting in a U-G base mismatch, which can be then
repaired back to C-G (27,28). Therefore, BrdU, just as
5-aza, can be incorporated in place of cytidine, thus
leading to the loss of CpG methylation. The down-
regulation of DNMTs may be a secondary effect of
BrdU-induced chromatin changes, which however
further promotes global CpG demethylation. Indeed,
DNA demethylation can be only achieved by replacement
of methylated cytosine by the DNA repair machinery or
by inhibited activity of DNMT enzymes during the DNA
replication process (17) and, in our experiments, differen-
tiation did neatly correlate with the reduced expression of
DNMTs. Also elsewhere, decreased DNMT activity and
reduced DNA methylation were shown to be associated
with NSC differentiation (21), while DNMT1 deﬁciency
(43) or inhibition of global DNA methylation (30–32)
were both reported to result in ectopic stem cell
differentiation.
Finally, our study suggests a word of caution when
using BrdU in stem cells studies and when interpreting
the results deriving from its use, especially in living
animals. Our data on forebrain NSC strongly implies
that also in vivo BrdU may indeed perturb stem cell physi-
ology in a similar way. Long-term BrdU administration
to mice in order to detect NSC may hence lead to ectopic
differentiation of NSC and to misinterpretation of data,
e.g. by assuming the proliferation of differentiated
cells. It is also possible that other somatic stem cell types
may respond to prolonged BrdU exposure in a similar
manner.
Bromodeoxyuridine (BrdU) is already used as a
radio-sensitization drug in cancer treatment (13). At the
same time, many approaches for cancer treatment aim at
targeting DNA methylation (e.g. by 5-aza) (33), or
inducing differentiation of so-called cancer stem cells,
thus depriving tumours of their repopulating capacity
and preventing relapse (44). Interestingly, while no DNA
demethylating effect of BrdU was seen in rat hepatoma
cells (22), the newly discovered BrdU substitute EdU was
shown to have anti-proliferative and apoptotic effects on
human glioblastoma cells (45), thus indicating that BrdU
may affect differently various cell types. In any case, we
suggest that BrdU and its related compounds should be
re-evaluated as an anti-cancer agent on the basis of its
unique potential to induce stem cell differentiation while
showing low toxicity to the patient.
SUPPLEMENTARY DATA
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